Oprelvekin

Summary

Oprelvekin (CHEMBL1201573) is an approved protein (ATC L03AC02); indicated across 10 conditions including thrombocytopenia and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AC02
• Indications: 10 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201573
Name	Oprelvekin
Type	Protein
Max phase	4
ATC	L03AC02

Also known as: Neumega, Oprelvekin, Oprelvekina, Oprelvekine, OPRELVEKIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Interleukin-11 receptor	Full agonist

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombocytopenia	4	MONDO:0002049	HP:0001873
neoplasm	4	MONDO:0005070	EFO:0000616
chronic myeloid leukemia	2	MONDO:0011996	EFO:0000339
hemophilia A	2	MONDO:0010602	MONDO:0010602
hematologic disorder	2	MONDO:0005570	HP:0001871
von Willebrand disease (hereditary or acquired)	2	MONDO:0024574	MONDO:0024574
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
MALT lymphoma	1	MONDO:0007650	EFO:0000191
Waldenstrom macroglobulinemia	1	MONDO:0100280	EFO:0009441
follicular lymphoma	1	MONDO:0018906	MONDO:0018906

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00012298	PHASE1/PHASE2	TERMINATED	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00524342	PHASE2	COMPLETED	IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
NCT00886743	PHASE2	TERMINATED	Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).